Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 3, 2025
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER

None of the SARS-CoV-2 Genetic Mutations Appear to Increase Transmissibility

ICRISAT Biological Science Research Technician Vacancy Available

ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER
  • BiotechToday
  • World

ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER

bioxone December 2, 2020December 2, 2020

Husna, Amity University Kolkata

Oncolytic viruses are genetically engineered for the destruction of cancer or tumour-causing cells specifically. They’re delivered for treatment inside the body via intravenous injection. In 2015, one such oncolytic virus was approved by the FDA for treating skin cancer, melanoma. A major obstacle in the application of oncolytic adenoviruses is that they face a barrier from the human immune system. The antibodies and blood components neutralize the injected adenovirus doses and also send it to the liver, the body’s garbage disposal. Some patients also developed inflammation and infection reaction on the application of oncolytic adenovirus.

Recently these barriers have been overcome by the researchers from the Pharmacology department of Case Western Reserve University. They’ve re-engineered the human adenovirus in such a way that it doesn’t get caught by parts of the innate immune system easily. Dmitry Shayakhmetov, PhD has stated that now it is possible to deliver the modified virus systemically at possible high doses for suppression of the tumour growth and even the life-threatening systemic toxicities or inflammatory reaction won’t get triggered anymore. Furthermore, the re-engineered adenoviruses can be armed with genes and proteins that can stimulate an immunity to cancer. 

The re-engineered adenovirus is therefore a technology which can be customized for various cancer patients and can be used as personalized life-saving therapy to patients with metastatic cancer.  

Also read:None of the SARS-CoV-2 Genetic Mutations Appear to Increase Transmissibility

SOURCE: 

https://scitechdaily.com/new-weapon-against-metastatic-cancer-engineered-stealth-bomber-virus/

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Related

Tagged adenovirus cancer engineered oncolytic adenovirus FDA infections inflammation inflammatory reactions injection innate immune system intravenously melanoma metastasis metastatic cancer oncolytic patients skin cancer technology therapy tumour cells tumour growth weapon

4 thoughts on “ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER”

  1. Diwita Roy says:
    December 2, 2020 at 4:00 pm

    Very well written. Illuminating content.

    Reply
  2. Pingback: DRY SWAB-DIRECT RT-PCR TO RAMP UP TEST FREQUENCY - BioXone
  3. sania says:
    December 3, 2020 at 11:23 am

    👍well written

    Reply
  4. Fathima Nifara says:
    December 7, 2020 at 1:54 pm

    As Iam very much interested in cancer biology, I personally like this article and its written in a very comprehensible manner.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

ICRISAT Biological Science Research Technician Vacancy Available

bioxone December 3, 2020

-Shristi Sharma, Team bioXone ICRISAT Biological Science Research Technician Vacancy Available. ICRISAT hiring for research vacancies for BSc Biological Sciences candidates with mentioned qualifications are eligible. Check out all the details posted below on the same:  Name of Job: Research Technician No. of Posts: 01 How to Apply: Candidates should apply on or before 17 […]

Related Post

  • BiotechToday
  • World

Paleontological studies interpose Dragon Man as our sister lineage

BioTech Today July 21, 2021July 21, 2021

Arya Sukumar, College of Agriculture, Vellayani Feeling utterly happy to share the news that we have discovered our long-lost sister lineage. Experts think that this skull represents a newly discovered human species called Homo longi, or “Dragon Man,” as it is the largest of all known Homo skulls. Unveiling the story of the Homo longi […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

Longer gap between vaccine doses: Effective or not?

BioTech Today July 8, 2021July 7, 2021

Anjali Kumari, IILM College of Engineering and Technology Longer gap (up to 45 weeks) between the Covid-19 vaccines may increase the immune response. According to a new study from the University of Oxford in the United Kingdom, it has been stated that a gap of up to 45 weeks between the first and second doses […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

1% of rivers globally found responsible for most plastic emissions into the ocean

bioxone May 15, 2021May 16, 2021

Sampriti Roy, University of Calcutta British philosopher Timothy Morton defines a hyperobject as something that is so widely distributed in space and time such that it surpasses spatiotemporal specificity. This concept applies to Global Warming, radioactive plutonium and something that is a constituent of at least one item in front of you right now- microplastic. […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy